Literature DB >> 12687590

Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed from clinical symptoms: a 10-year retrospective study in a French region (Brittany).

D Siret1, G Bretaudeau, B Branger, A Dabadie, M Dagorne, V David, M de Braekeleer, V Moisan-Petit, G Picherot, G Rault, V Storni, M Roussey.   

Abstract

Until the year 2000, systematic cystic fibrosis (CF) neonatal screening was only performed in a few regions of France. The Brittany region began in 1989, but not the neighboring region of Loire-Atlantique. The present study compares the clinical evolution of both affected populations 10 years after screening was started. Although the 77 screened and 36 nonscreened children were followed in different CF centers, they were included in similar care protocols. The clinical characteristics at diagnosis and their evolution over a 10-year period of all the children affected with CF and born between January 1, 1989 and December 31, 1998, excluding those with meconium ileus, were compared. There were no significant differences in sex ratio, gestational age, anthropometric data at birth, frequency of deltaF508 homozygotes, proportion of pancreatic-insufficient patients, and mean age between the two populations. Age at diagnosis was lower in the screened group (38 days vs. 472 days, P < 10(-7)), as was the delay in supplementation with pancreatic enzymes (1.7 months vs.15.9 months, P < 10(-7)). The proportion of children who were hospitalized at least once was higher among the nonscreened than the screened patients (86% vs. 49%, P < 10(-4)). Z-scores for weight and height were significantly better in the screened population, not only in the first years of life, but also at 5 years old for height and 8 years old for weight. The Shwachman and Brasfield scores were higher among the screened children during the whole period of follow-up. No significant differences in colonization by Pseudomonas aeruginosa nor in lung function were found. Given the homogeneity in the characteristics and the follow-up of both populations, the benefits in terms of nutrition and clinical well-being of neonatal screening appear to be clear, thus confirming the advantages of its general implementation. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12687590     DOI: 10.1002/ppul.10259

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  12 in total

1.  The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience.

Authors:  Scott D Grosse; John D Thompson; Yao Ding; Michael Glass
Journal:  Milbank Q       Date:  2016-06       Impact factor: 4.911

2.  Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening.

Authors:  Michael J Rock; Hara Levy; Christina Zaleski; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2011-08-24

3.  Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.

Authors:  Olaf Sommerburg; Martin Lindner; Martina Muckenthaler; Dirk Kohlmueller; Svenja Leible; Reinhard Feneberg; Andreas E Kulozik; Marcus A Mall; Georg F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2010-08-17       Impact factor: 4.982

4.  Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.

Authors:  Daniel H Leung; Sonya L Heltshe; Drucy Borowitz; Daniel Gelfond; Margaret Kloster; James E Heubi; Michael Stalvey; Bonnie W Ramsey
Journal:  JAMA Pediatr       Date:  2017-06-01       Impact factor: 16.193

Review 5.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

6.  Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening.

Authors:  Aimee C Walsh; Gilles Rault; Zhanhai Li; Virginie Scotet; Ingrid Duguépéroux; Claude Férec; Michel Roussey; Anita Laxova; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2009-11-18       Impact factor: 5.482

7.  Cystic fibrosis: benefits and clinical outcome.

Authors:  K O McKay
Journal:  J Inherit Metab Dis       Date:  2007-07-06       Impact factor: 4.982

8.  Delays in diagnosing cystic fibrosis: can we find ways to diagnose it earlier?

Authors:  Michelle Steinraths; Hilary D Vallance; A George F Davidson
Journal:  Can Fam Physician       Date:  2008-06       Impact factor: 3.275

9.  Is newborn screening for cystic fibrosis a basic human right?

Authors:  Philip M Farrell
Journal:  J Cyst Fibros       Date:  2008-02-11       Impact factor: 5.482

10.  Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.

Authors:  Joseph F Levy; Marjorie A Rosenberg; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2016-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.